US 2013/0172318 A1Published application

Anti-inflammatory agents

OwnerDavid John Grainger, David John Foxinventors

Life of this patent

Estimating the term…

Abstract

Disclosed herein are methods of preventing or treating inflammatory diseases using 3-aminolactam compounds, each with aromatic “tail groups”. Compounds as defined by formulae (I) and (I′), and the medical uses of the compounds, are described herein.

Claims25

Dependent claims

A compound of formula (I), or a pharmaceutically acceptable salt thereof:

wherein:
n is an integer from 1 to 4;
k is an integer from 0 to 5, representing the number of groups substituting C2, C3, C4, C5 and/or C6 of the phenyl ring;
and
X are linear or branched groups substituting the phenyl ring independently selected from any one of the groups consisting of:
alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl, carboxyl, and halogen;
with the proviso that:
when on the phenyl ring C2, C5 and C6 are unsubstituted, and C4 is unsubstituted or is substituted with an hydroxy, alkoxy, amino, alkylamino, dialkylamino, or halogen group, then C3 is substituted with a halogen group;
and
when on the phenyl ring C2, C5 and C6 are unsubstituted, and C3 is unsubstituted or is substituted with an alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino or carboxyl group, then C4 is substituted with any one of the group consisting of:
alkyl group, haloalkyl group, hydroxyalkyl group, and carboxyl group.

8 more elements

A compound of formula (I′), or a pharmaceutically acceptable salt thereof:

wherein:
n is an integer from 1 to 4;
k is an integer from 0 to 5, representing the number of groups substituting C2, C3, C4, C5 and/or C6 of the phenyl ring;
and
X are linear or branched groups substituting the phenyl ring independently selected from any one of the groups consisting of:
alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl, carboxyl, and halogen;
with the proviso that:
when on the phenyl ring C2, C5 and C6 are unsubstituted, and C4 is unsubstituted or is substituted with an hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl, or halogen group, then C3 is substituted with a halogen group:
and
when on the phenyl ring C2, C5 and C6 are unsubstituted, and C3 is unsubstituted or is substituted with an alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl or carboxyl group, then C4 is substituted with any one of the group consisting of:
alkyl group, haloalkyl group, hydroxyalkyl group, and carboxyl group.

8 more elements

A compound of formula (I):

wherein:
n is an integer from 1 to 4;
k is an integer from 1 to 5, representing the number of groups substituting C2, C3, C4, C5 and/or C6 of the phenyl ring;
with the provisos that:
when n is 1 or 2, X are linear or branched groups independently selected from any one of the group consisting of:
C7 or higher alkyl, haloalkyl with a C7 or higher alkyl group, hydroxyalkyl with a C7 or higher alkyl group, C7 or greater alkoxy, aminoalkyl with a C4 or higher alkyl group, aminodialkyl with two C4 or higher alkyl groups, and carboxy;
when n is 3 or 4, X are linear or branched groups independently selected from any one of the group consisting of:
alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl, carboxy, and halogen;
when n is 3 or 4 and on the phenyl ring C2, C5 and C6 are unsubstituted, and C4 is unsubstituted or is substituted with an hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl, or halogen group, then C3 is substituted with a halogen group;
when n is 3 or 4 and on the phenyl ring C2, C5 and C6 are unsubstituted, and C3 is unsubstituted or is substituted with an alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl or carboxy group, then C4 is substituted with any one of the group consisting of:
alkyl group, haloalkyl group, hydroxyalkyl group, and carboxy group;
and when n=3, X is other than 4′-methoxy, 3′-trifluoromethyl, or 3′,4′,5′-trimethoxy, provided that the compound is not one of the group consisting of:
3-(3′-trifluoromethylbenzoylamino)-caprolactam,
3-(4′-methylbenzoylamino)-caprolactam,
3-(2′-aminobenzoylamino)-caprolactam,
3-(3′,4′-dimethoxybenzoylamino)-caprolactam,
3-(3′,5′-di-tert-butyl-4′-hydroxybenzoylamino)-caprolactam,
3-(2′,4′-dimethoxybenzoylamino)-caprolactam,
3-(3′-methoxybenzoylamino)-caprolactam,
3-(4′-trifluoromethylbenzoylamino)-caprolactam,
3-(2′,3′,4′-trimethoxybenzoylamino)-caprolactam,
3-(2′,6′-difluoromethylbenzoylamino)-caprolactam,
3-(2′-fluoromethylbenzoylamino)-caprolactam,
3-(2′-amino-3′-hydroxy-4′-methylbenzoylamino)-caprolactam, and
3-(3′,5′-dimethylbenzoylamino)-caprolactam.

22 more elements

Dependencies are inferred from the claim text.

patentgrep

Loading patent…

Back to results

US 2013/0172318 A1Published application

Anti-inflammatory agents

OwnerDavid John Grainger, David John Foxinventors

Life of this patent

Estimating the term…

Abstract

Claims25

Dependent claims

A compound of formula (I), or a pharmaceutically acceptable salt thereof:

wherein:
n is an integer from 1 to 4;
k is an integer from 0 to 5, representing the number of groups substituting C2, C3, C4, C5 and/or C6 of the phenyl ring;
and
X are linear or branched groups substituting the phenyl ring independently selected from any one of the groups consisting of:
alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl, carboxyl, and halogen;
with the proviso that:
when on the phenyl ring C2, C5 and C6 are unsubstituted, and C4 is unsubstituted or is substituted with an hydroxy, alkoxy, amino, alkylamino, dialkylamino, or halogen group, then C3 is substituted with a halogen group;
and
when on the phenyl ring C2, C5 and C6 are unsubstituted, and C3 is unsubstituted or is substituted with an alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino or carboxyl group, then C4 is substituted with any one of the group consisting of:
alkyl group, haloalkyl group, hydroxyalkyl group, and carboxyl group.

8 more elements

A compound of formula (I′), or a pharmaceutically acceptable salt thereof:

wherein:
n is an integer from 1 to 4;
k is an integer from 0 to 5, representing the number of groups substituting C2, C3, C4, C5 and/or C6 of the phenyl ring;
and
X are linear or branched groups substituting the phenyl ring independently selected from any one of the groups consisting of:
alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl, carboxyl, and halogen;
with the proviso that:
when on the phenyl ring C2, C5 and C6 are unsubstituted, and C4 is unsubstituted or is substituted with an hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl, or halogen group, then C3 is substituted with a halogen group:
and
when on the phenyl ring C2, C5 and C6 are unsubstituted, and C3 is unsubstituted or is substituted with an alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl or carboxyl group, then C4 is substituted with any one of the group consisting of:
alkyl group, haloalkyl group, hydroxyalkyl group, and carboxyl group.

8 more elements

A compound of formula (I):

wherein:
n is an integer from 1 to 4;
k is an integer from 1 to 5, representing the number of groups substituting C2, C3, C4, C5 and/or C6 of the phenyl ring;
with the provisos that:
when n is 1 or 2, X are linear or branched groups independently selected from any one of the group consisting of:
C7 or higher alkyl, haloalkyl with a C7 or higher alkyl group, hydroxyalkyl with a C7 or higher alkyl group, C7 or greater alkoxy, aminoalkyl with a C4 or higher alkyl group, aminodialkyl with two C4 or higher alkyl groups, and carboxy;
when n is 3 or 4, X are linear or branched groups independently selected from any one of the group consisting of:
alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl, carboxy, and halogen;
when n is 3 or 4 and on the phenyl ring C2, C5 and C6 are unsubstituted, and C4 is unsubstituted or is substituted with an hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl, or halogen group, then C3 is substituted with a halogen group;
when n is 3 or 4 and on the phenyl ring C2, C5 and C6 are unsubstituted, and C3 is unsubstituted or is substituted with an alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, amino, aminoalkyl, aminodialkyl or carboxy group, then C4 is substituted with any one of the group consisting of:
alkyl group, haloalkyl group, hydroxyalkyl group, and carboxy group;
and when n=3, X is other than 4′-methoxy, 3′-trifluoromethyl, or 3′,4′,5′-trimethoxy, provided that the compound is not one of the group consisting of:
3-(3′-trifluoromethylbenzoylamino)-caprolactam,
3-(4′-methylbenzoylamino)-caprolactam,
3-(2′-aminobenzoylamino)-caprolactam,
3-(3′,4′-dimethoxybenzoylamino)-caprolactam,
3-(3′,5′-di-tert-butyl-4′-hydroxybenzoylamino)-caprolactam,
3-(2′,4′-dimethoxybenzoylamino)-caprolactam,
3-(3′-methoxybenzoylamino)-caprolactam,
3-(4′-trifluoromethylbenzoylamino)-caprolactam,
3-(2′,3′,4′-trimethoxybenzoylamino)-caprolactam,
3-(2′,6′-difluoromethylbenzoylamino)-caprolactam,
3-(2′-fluoromethylbenzoylamino)-caprolactam,
3-(2′-amino-3′-hydroxy-4′-methylbenzoylamino)-caprolactam, and
3-(3′,5′-dimethylbenzoylamino)-caprolactam.

22 more elements

Dependencies are inferred from the claim text.